Table 2.

Unadjusted and Adjusted Cox Model Estimates for Risk of EBV Acquisition Isotype-Specific Binding to EBV Glycoproteins

Antibody Isotype Specific to EBV Glycoprotein	HEU vs HUU t (P Value)	Unadjusted HR (95% CI)	P Value	Adjusted HRa (95% CI)	P Value
IgG1 to gp350	0.86 (.400)	1.00 (.99–1.00)	.178	1.00 (.99–1.00)	.405
IgG1 to gH/gL	3.21 (.004)	1.00 (.99–1.01)	.231	1.00 (.99–1.00)	.679
IgG1 to gp42	2.25 (.033)	1.00 (.99–1.00)	.335	0.99 (.99–1.00)	.746
IgG1 to gB	0.08 (.940)	0.99 (.99–1.00)	.927	0.99 (.99–1.00)	.773
IgG1 to TT	−3.26 (.003)	1.00 (.99–1.00)	.101	1.00 (.99–1.00)	.786
IgG2 to gp350	2.53 (.023)	1.01 (1.00–1.02)	.012	1.01 (.99–1.01)	.210
IgG2 to gH/gL	−0.73 (.473)	1.12 (.92–1.37)	.261	1.29 (1.03–1.60)	.024
IgG2 to gp42	1.03 (.319)	1.19 (.90–1.58)	.230	1.05 (.79–1.39)	.743
IgG2 to gB	1.57 (.137)	1.00 (.99–1.01)	.572	1.00 (.99–1.01)	.665
IgG2 to TT	−2.82 (.009)	1.00 (.99–1.00)	.254	1.00 (.99–1.00)	.620
IgG3 to gp350	1.75 (.100)	1.01 (.99–1.01)	.077	1.00 (.99–1.00)	.367
IgG3 to gH/gL	2.27 (.036)	1.05 (.95–1.16)	.354	0.98 (.88–1.09)	.679
IgG3 to gp42	0.42 (.676)	0.93 (.77–1.11)	.416	0.83 (.67–1.03)	.089
IgG3 to gB	1.57 (.137)	1.00 (.99–1.00)	.172	1.00 (.99–1.00)	.651
IgG3 to TT	0.48 (.634)	1.00 (.99–1.00)	.278	1.00 (.99–1.00)	.448
IgG4 to gp350	1.72 (.096)	1.41 (.60–3.3)	.432	0.84 (.35–2.01)	.694
IgG4 to gH/gL	0.57 (.576)	1.09 (.55–2.18)	.799	1.09 (.55–2.17)	.803
IgG4 to gp42	0.19 (.847)	1.00 (.30–3.4)	.990	1.94 (.52–7.34)	.325
IgG4 to gB	0.75 (.460)	1.25 (.91–1.73)	.170	1.27 (.91–1.78)	.155
IgG4 to TT	−1.18 (.249)	1.00 (.99–1.00)	.617	1.00 (.99–1.00)	.467

Bold values indicate statistical significance.

Abbreviations: CI, confidence interval; EBV, Epstein-Barr virus; HEU, HIV-exposed uninfected infants; HIV, human immunodeficiency virus; HR, hazard ratio; HUU, HIV-unexposed uninfected infants.

^aMultivariate analysis adjusted for maternal HIV status.